Research and Development is categorized into two functional groups one group has been working on Development of recombinant vaccines and other one has been working on Development of biosimilar molecules.
Each group consists the following divisions: Molecular Biology, Translational science, Bioanalysis, Pharmacology and Drug safety evolution.
The R&D team of Krijan Biotech is composed of highly experienced and industrial experts. For future research the organization is collaborating with Universities, Research institutions and Trust based hospitals.
Our mission is “Innovating for Life” to develop innovative vaccines and Biological therapeutics for global patients with unmet medical needs.
We have isolated and developed 40 different probiotic strains and technology establishment for different enzymes. It has been catering to Aquaculture, veterinary and Human pharma sectors. We are focused on “best-in-class” and “first-in-class” recombinant vaccines and therapeutic proteins to treat different viral infections and inflammatory diseases.
We follow international quality standards for our product development and adhere to regulatory requirements of the DCGI, FDA and EMA. “Innovation and quality” are the soul of KRIJAN BIOTECH in the generation of scientific data and in the processes of drug discovery, development, and manufacturing. We are committed to bringing innovative vaccines and bio-similar drugs in India, the US, Europe, and other developing countries.
Our products are in the stages of Research and Development.FPSG-1705, a potential best-in-class recombinant vaccine for small ruminants, HABCD-1812 -recombinant vaccine for hepatitis, and other bio-similar molecules.